This Week in Pediatric Oncology

This Week in Pediatric Oncology header image 1

Entries Tagged as 'neuroblastoma'

TWIPO #66 - Interview with Dr. Rani George

October 2nd, 2017 · Comments

Host Dr. Ryan Roberts, from Nationwide Children's Hospital in Columbus, Ohio, is joined by Dr. Rani George to discuss her experience with studying neuroblastoma and how she got involved in the field of oncology. George discusses her thoughts on what is needed to progress pediatric cancer research - including relapse biopsies, understanding the biology, and, of course, funding. As Dr. Roberts says, what we need is, "...more time, more patience, and more funding."  Please send questions and comments to 


Tags: cancer · children · pediatric cancer · childhood cancer · drug development · neuroblastoma · research · immunotherapy · Advancement in Cancer Research

TWiPo #59 ~ Interview with Dr. Sajid Qureshi

October 17th, 2016 · Comments

Host Dr. Timothy Cripe and co-Host Nilay Shah interview Dr. Sajid Qureshi, a professor of Pediatric Oncology at the Tata Memorial Center, Mumbai, India. Dr. Qureshi is an Executive Committee Member of the International Society of Pediatric Surgical Oncology (IPSO). In this episode Dr. Qureshi provides a fascinating, first-hand glimpse into the successes and challenges of delivering quality care to larger, as well as remote, pediatric cancer populations. The episode concludes with Dr. Qureshi's thoughts on how international research collaboration could provide access to relapsed children worldwide.


Tags: families · cancer · children · pediatric cancer · childhood cancer · drug development · neuroblastoma · research · brain tumor · clinical trials · Advancement in Cancer Research

TWiPO #58 ~ Interview with Dr. Damon Reed

October 17th, 2016 · Comments

TWiPO Host Dr. Timothy Cripe, with co-hosts Dr. Nilay Shah and Dr. Bhuvana Setty welcome Dr. Damon Reed, Director of the Adolescent and Young Adult Program at Moffitt Cancer Center and Leader of the Pediatric Cancer Foundation's pediatric phase I consortium, the Sunshine Project. Dr. Reed shares his view points on how we can improve and accelerate the current trajectory with regard to pediatric therapy development. 


Tags: families · cancer risk · cancer · children · pediatric cancer · childhood cancer · drug development · neuroblastoma · medulloblastoma · sarcoma · research · brain tumor · immunotherapy · clinical trials · Advancement in Cancer Research

TWIPO #56 ~ Interview with Dr. Mark Hatley

September 6th, 2016 · Comments

On today's podcast, TWIPO host Dr. Timothy Cripe (Nationwide Children’s Hospital) and co-host Dr. Ryan Roberts (Nationwide Children’s Hospital) interview Dr. Mark Hatley (St. Jude Children's Research Hospital). Dr. Hatley discusses how he got into the field of Biological Chemistry in Oncology. Also Dr. Hatley gives an indepth explaination about his research in G-Proteins.


Tags: cancer · children · pediatric cancer · childhood cancer · drug development · neuroblastoma · medulloblastoma · research · brain tumor · immunotherapy · clinical trials · Advancement in Cancer Research

TWIPO #52 ~ Interview with Dr. James Geller

December 9th, 2015 · Comments

On this TWiPO episode hosts, Dr. Timothy Cripe and Dr. Nilay Shah (Nationwide Children’s Hospital) interview Dr. James Geller (Medical Director at Kidney and Liver Tumors Program, Co-Medical Director at Retinoblastoma Program, Associate Director at Global Cancer Programs, Associate Professor at UC Department of Pediatrics.) Dr. James Geller was one of the original TWiPO members back in 2010. Today Dr. Geller talks about the battle to get access to potential drugs (Ex. Lorvotuzumab [IMGN901]) that can be beneficial to treating pediatric cancers.


Tags: cancer · children · pediatric cancer · childhood cancer · drug development · neuroblastoma

TWIPO #48 ~ Interview With Dr. Michael D. Hogarty

April 20th, 2015 · Comments

TWiPO host Dr. Nilay Shah (Nationwide Children’s Hospital) interviews Dr. Michael D. Hogarty, MD, an attending physician in the Division of Oncology at The Children's Hospital of Philadelphia. Dr. Hogarty recalls his efforts in finding a new way of tackling neuroblastoma by sending 17,000 tumor samples around the world. In this short interview, he discusses his current work in the lab, which involves testing the MYC gene found in children with high-risk neuroblastoma.


Tags: neuroblastoma · research

TWIPO #47 ~ Interview With Dr. Hiro Shimada

March 30th, 2015 · Comments

TWiPo co-hosts Dr. Keri Stretby (Nationwide Children’s Hospital) and Dr. Nilay Shah (Nationwide Children’s Hospital) interview Hiroyuki Shimada, MD, PhD, Professor of Clinical Pathology at the Children’s Hospital of Lost Angeles. Dr. Shimada developed the Shimada neuroblastoma classification system for neuroblastoma, which was the basis of The International Neuroblastoma Pathology Classification and now The International Neuroblastoma Risk Group classification system.


Tags: neuroblastoma

TWIPO #46 ~ ANR Recap: Interview With Dr. Sue Cohn

March 30th, 2015 · Comments

TWiPO host Dr. Nilay Shah (Nationwide Children’s Hospital) interviewed Susan L. Cohn, MD, a Professor of Pediatrics, Dean of Clinical Research at the University of Chicago at the ANR meeting in Cologne, Germany last year for this episode of This Week in Pediatric Oncology. Dr. Cohn is a highly respected expert in pediatric cancers and blood diseases. She is a leading authority on neuroblastoma and actively researching several aspects of neuroblastoma. Her research has received generous support from the National Institutes of Health/National Cancer Institute and the National Institute of Neurological Disorders and Stroke. Dr. Shaw and Dr. Cohn discuss the future of neuroblastoma research and clinical trial design to create more effective treatment options for children with high-risk disease.


Tags: neuroblastoma · clinical trials · ANR Meeting

TWIPO #44 ~ ANR Recap: Interview With Professor Michelle Haber and Professor Andrew Pearson

November 10th, 2014 · Comments

In the most recent episode of This Week in Pediatric Oncology (TWiPO), the first podcast focusing on pediatric cancer research, co-hosts Dr. Keri Stretby (Nationwide Children’s Hospital) and Dr. Nilay Shah (Nationwide Children’s Hospital), caught up with Professor Michelle Haber (Executive Director at Children’s Cancer Institute in Australia and Professor Andrew Pearson of the Cancer Research UK. In this 26-minute podcast, both researchers discuss the future of neuroblastoma, specifically looking at precision medicine, the role of gene sequencing and the role of international collaboration to bring new therapies into the clinic.


Tags: neuroblastoma

TWIPO #42 ~ Advances in Neuroblastoma Research Meeting Recap: Interview With Frank Berthold

July 23rd, 2014 · Comments

New York – This Week in Pediatric Oncology presents the third and final interview from the recent Advances in Neuroblastoma Research meeting, which was held in Cologne, Germany, in May. Co-hosts Dr. Nilay Shah (Nationwide Children’s Hospital) and Dr. Keri Stretby (Nationwide Children’s Hospital) talk with Frank Berthold, ANR2014 Local Chairman, to discuss meeting highlights in the short, 18-minute interview.  


Tags: neuroblastoma · ANR Meeting

TWIPO #41 ~ Advances in Neuroblastoma Research Meeting Recap: Advances in Understanding MIBG Therapy

July 15th, 2014 · Comments

New York – This Week in Pediatric Oncology presents the second in a series of interviews from the recent Advances in Neuroblastoma Research meeting, which was held in Cologne, Germany, in May. Co-hosts Dr. Nilay Shah (Nationwide Children’s Hospital) and Dr. Keri Stretby (Nationwide Children’s Hospital) discuss MIBG therapy in treating children with high-risk neuroblastoma with Dr. Kate Matthay (UCSF Benioff Children's Hospital) and Dr. Gregory Yanik (C.S. Mott Children’s Hospital at the University of Michigan). In this 45-minute interview, both Drs. Matthay and Yanik, who have conducted extensive research in MIBG throughout their long careers, share their perspectives on what’s going on in the field now and opportunities to improve the therapy in the future.


Tags: neuroblastoma · MIBG · ANR Meeting

TWiPO #26 ~ Killer Immunoglobulin Receptor (KIR) Mismatch in Neuroblastoma

February 10th, 2014 · Comments

May 07, 2012

In this interesting episode, host Dr. Tim Cripe (Nationwide Children's) and co-hosts Dr. Lionel Chow (Cincinnati Children's), Dr. Andy Kolb (AI DuPont), and Donna Ludwinski (Solving Kids' Cancer) quiz Dr Paul Sondel and Dr. Ken DeSantes (both from University of Wisconsin - Madison) on NK cells and the implications of KIR/KIR-ligand mismatch (killer immunoglobulin-like receptor) with regard to immunotherapy treatment of neuroblastoma.


Delgado DC, Hank JA, Kolesar J, Lorentzen D, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010 Dec 1;70(23):9554-61. Epub 2010 Oct 8.


Venstrom JM, Zheng J, Noor N, Danis KE, et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res. 2009 Dec 1;15(23):7330-4. Epub 2009 Nov 24.


Alderson KL, Sondel PM. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol. 2011;2011:379123. Epub 2011 May 24.


Tags: neuroblastoma · immunotherapy

TWiPO #23 ~ Neuroblastoma Jeopardy 2011

February 10th, 2014 · Comments

January 26, 2012

In 2011 there were over 1300 new articles published on neuroblastoma in the medical literature.

Join Dr. Tim Cripe and his co-host Dr. Lars Wagner in a fast-paced, in-depth, and comprehensive survey of 18 of the most important papers on neuroblastoma published in 2011. Dr. Cripe and Dr Wagner explore and discuss the compelling evidence reported on a variety of topics, including epidemiology, risk stratification, clinical trials, ALK mutation and expression, new targets, and genetics.

All of the papers discussed are listed HERE with links to PubMed.

Please send all comments and questions to


Tags: childhood cancer · neuroblastoma

TWiPO #19 ~ More on Hedgehog signaling, brain tumor risk from cell phone use, and FDA approval of cancer drugs

February 10th, 2014 · Comments

October 30, 2011

Several just-published papers in the literature relate to recent podcast episodes, and host Dr. Tim Cripe and co-host Dr.  Lionel Chow review these interesting developments.

0:55 Hedgehog Signaling: Recent papers discussing this pathway in neuroblastoma and rhabdomyosarcoma are discussed, with implications for treatment in these tumor types with itraconozole.

6:40 Cell phone and brain tumor risk: The controversy concerning criticism by the Environmental Health Trust of a study showing that cell phone use does not increase risk of brain tumors in children is explored.

Accelerated approval of cancer drugs by the FDA and implications for pediatric cancers.

15:30 Brentuximab for two types of lymphoma

21:20 Vemurafenib for melanoma

28:30 Crizotinib for non-small cell lung cancer (and potential use in neuroblastoma)

42:30 Response to email regarding personalized medicine TWiPO episode #17 and lab blog for Dr Charles Keller at OHSU


Pediatr Blood Cancer. 2011 Dec 1;57(6):930-8. doi: 10.1002/pbc.23174. Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group.

Int J Oncol. 2011 Oct;39(4):899-906. doi: 10.3892/ijo.2011.1076. Pharmacological inhibition of the Hedgehog pathway preventshuman rhabdomyosarcoma cell growth.

Cancer Lett. 2011 Nov 28;310(2):222-31. Inhibition of the sonic hedgehog pathway by cyplopaminereduces the CD133+/CD15+ cell compartment and the in vitrotumorigenic capability of neuroblastoma cells.

Cell Phone Study Was Flawed, Say Some Experts by Roxanne Nelson Medscape Oncology News.

The JNCI Study by Aydin et al on Risk of Childhood Brain Cancer from Cellphone Use Reveals Serious Health Problems, Environmental Health Trust.

N Engl J Med. 2010 Nov 4;363(19):1812-21. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

FDA Approves Brentuximab for Two Lymphomas By: ELIZABETH MECHCATIE, Oncology Report Digital Network.

Clin Cancer Res. 2011 Oct 15;17(20):6428-36. Brentuximab Vedotin (SGN-35).

FDA Approves Vemurafenib for Advanced Melanoma. By: JANE SALODOF MACNEIL, Oncology Report Digital Network.

N Engl J Med. 2011 Jun 30;364(26):2507-16. Improved survival with vemurafenib in melanoma with BRAFV600E mutation.

N Engl J Med. 2011 Jun 30;364(26):2547-8. Been there, not done that--melanoma in the age of molecular therapy.

Biochem J. 2011 Aug 15. Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.

N Engl J Med. 2010 Oct 28;363(18):1693-703. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Nature. 2007 Aug 2;448(7153):561-6. Epub 2007 Jul 11. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Science. 1994 Mar 4;263(5151):1281-4. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.


Tags: children · childhood cancer · neuroblastoma · sarcoma

TWiPO #17 ~ Personalized medicine: Interview with Dr Giselle Sholler

February 10th, 2014 · Comments

October 13, 2011

Host Dr. Tim Cripe and co-hosts Dr. Lars Wagner and Dr. Lionel Chow welcome guest Dr. Giselle Sholler on this episode of TWiPO. Dr. Sholler gives the background to her current research interest in neuroblastoma, and describes her nifurtimox trials and how she formed the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC). The physicians also discuss the specifics of the personalized medicine feasibility trial now open for neuroblastoma.

Dr. Sholler is a Pediatric Oncologist with Spectrum Health Medical Group, Helen DeVos Childrens Hospital, and directs the Pediatric Oncology Therapeutic Discovery Clinic. She is also Co-Director of the VARI/TGen Pediatric Oncology Research Program, and Associate Professor of the Neuroblastoma Translational Research Laboratory at Van Andel Research Institute. She has a faculty appointment within Michigan State University's College of Human Medicine, and continues as adjunct faculty at University of Vermont. Dr. Sholler is also a Guest Researcher in the Pediatric Oncology Branch at the NCI.


J Clin Oncol. 2010 Nov 20;28(33):4877-83. Epub 2010 Oct 4. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

Science 16 Sept 2011: Vol. 333 no. 6049 pp. 1569-1571. Pushing the Envelope in Neuroblastoma Therapy

Mol Cancer Ther August 2011 10; 1311. A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer


Tags: children · childhood cancer · neuroblastoma

TWiPO #14 ~ Interview with Dr Kate Matthay

February 10th, 2014 · Comments

August 24, 2011

In this enlightening interview with Dr. Kate Matthay, a reknown leader in the neuroblastoma research community, host Dr. Tim Cripe draws out the inspiration for her early interest in medicine and why her career grew with a focus on neuroblastoma. Dr. Matthay explains the history and challenges of clinical research for neuroblastoma:

10:00 challenges in planning and conducting the CCG-3891 double randomized trial questioning the need for transplant and cis-retinoic acid

15:00 discussion of the COG-A3973 trial questioning the need for purged stem cells

15:50 rationale for the COG-ANBL0532 single versus tandem transplant trial

16:13 discussion of the COG-ANBL0032 ch14.18 with cytokines trial

18:00 MIBG COG pilot trial

22:00 work with SIOP and NB protocol development for children in Morocco (N Africa)

Please send any questions or comments to


Tags: children · childhood cancer · neuroblastoma

TWiPO #3 ~ Vincristine Pharmacogenetics, Irinotecan/Temozolomide for Relapsed Neuroblastoma

February 10th, 2014 · Comments

April 25, 2011

In this third episode, host Tim Cripe, MD, PhD, asks his co-hosts to discuss two recent papers that provide new information about genetic predisposition to increased toxicity to vincristine in some children, and the results of a phase II study using a combination therapy (irinotecan and temozolomide) in relapsed or refractory neuroblastoma.

1:24 Maureen O'Brien, MD discusses "Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia" in Pediatr Blood Cancer. 2011 Mar;56(3):361-7. doi: 10.1002/pbc.22845. Epub 2010 Nov 11.

22:10 Lars Wagner, MD discusses "Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study" from J Clin Oncol. 2011 Jan 10;29(2):208-13. Epub 2010 Nov 29.


Tags: children · childhood cancer · neuroblastoma